Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 19, 2021Expert Review of HematologyOpen Access

Phase II single-arm study of brentuximab vedotin in Chinese patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

YSYuqin SongYGYe GuoHHHuiqiang Huang

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Song et al. (2021) studied this question.

synapsesocial.com/papers/6a79e49d4c448619ca0decffhttps://doi.org/10.1080/17474086.2021.1942831
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Adult systemic anaplastic large-cell lymphoma: recommendations for diagnosis and management2015 · 26 citations
  2. 2Novel Therapies and Approaches to Relapsed/Refractory HL Beyond Chemotherapy2019 · 13 citations
  3. 3Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma2016 · 398 citations
  4. 4Population Pharmacokinetic Modeling and Exposure–Response Assessment for the Antibody‐Drug Conjugate Brentuximab Vedotin in Hodgkin's Lymphoma in the Phase III ECHELON‐1 Study2019 · 31 citations
  5. 5Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study2012 · 1,001 citations